1
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
1
Other hematologic neoplasm
1
Conditions
Neoplasms
1
Hematologic Neoplasms
1
Interventions
Cisplatin
3193
Cyclophosphamide
3187
Carboplatin
2968
Radiotherapy
2784
Paclitaxel
2716
Gemcitabine
2569
pembrolizumab
2378
Bevacizumab
2206
Docetaxel
2196
Fluorouracil
1848
Capecitabine
1828
Oxaliplatin
1738
Dexamethasone
1604
Nivolumab
1580
Doxorubicin
1501
Rituximab
1487
Magnetic Resonance Spectroscopy
1382
Etoposide
1345
Irinotecan
1245
Leucovorin
1222
Drug Therapy
1202
Cytarabine
1130
Pemetrexed
1074
fludarabine
1056
Specimen Handling
1009
Vincristine
964
Cetuximab
943
Prednisone
940
Trastuzumab
940
Lenalidomide
937
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
kalinox
×
Clear all
NCT03755895
2025-10-03
HYCUDES
Institut de Cancérologie de Lorraine
Phase 2
Completed
68 enrolled
NCT03483194
2020-06-23
REVEH
Weprom
Phase 2/3
Completed
126 enrolled